Bölümler
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:
Dirk Lange, CEO at Pyramid LabsBrett Alderson, President & Site Leader at NovaCinaJohn Cameron, Director, Global Injectables Platform at Corden PharmaJanet Hoogstraate, CEO at NorthX BiologicsYour host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dirk, Brett, John & Janet, focusing on:
Maximizing GLP-1 manufacturing capacity: Discussing Novo Nordisk’s recent acquisition of Catalent’s manufacturing facilities to bolster GLP-1 production capabilitiesIndustry consolidation: What this acquisition means for the pharmaceutical outsourcing industry and its impact on competition among CDMOsMeeting surging demand: Exploring how this move positions Novo Nordisk to respond to the rapidly increasing demand for GLP-1 receptor agonists, like those used in diabetes and obesity treatmentsStrategic manufacturing: The implications of integrating Catalent’s capabilities into Novo Nordisk’s operations and what it means for the broader CDMO sectorWith GLP-1 drugs at the forefront of diabetes and obesity treatment, Novo Nordisk's strategic acquisition of Catalent aims to strengthen its supply chain and boost production capacity to meet global demand. Our guests provide in-depth insights into how this acquisition could shape the future of drug development and outsourcing across the industry.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Stevenson, Independent Director and Pharma industry veteran.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:
Bringing an outsourcing model from UpjohnPharmacia into Pfizer and then driving manufacturing out of Pfizer into CDMOs without compromising on quality or IPBehind the scenes of Pfizer's mammoth acquisitions of Wyeth and HospiraThe failure to spend too much time setting up a reliable, high-quality outsourcing network in ChinaThe different perspectives of being 'the mayor of one huge site' to having a diversified, helicopter view across severalSwitching from buy-side external outsourcing to running Pfizer's CDMO division Pfizer CentreOneDon't be penny-wise and pound-foolish when balancing the onshoring manufacturing conundrum and how price controls in the US will impact all aspects of the industryPeter Stevenson is a leader in the pharmaceutical industry with extensive manufacturing and commercial experience. He was a Pfizer’s Global Manufacturing Leadership Team member, responsible for global procurement, global external supply, and a portfolio of Pfizer's internal manufacturing sites in North America, Europe, and Asia. Today, he is a Non-Executive Independent Board Member at Piramal Pharma.
Later, Mr. Stevenson served as General Manager of Pfizer’s contract manufacturing business and Value Stream Leader for the Injectables and Hospital Products Value Stream. Mr. Stevenson recently retired from Pfizer and serves as the Board Vice-Chair for Uniting to Combat Neglected Tropical Diseases and Chair of the Governance Committee.
Earlier in his career, Mr. Stevenson held positions at Rhone Poulenc and Celanese, including a 3-year expatriate assignment in France. He has a Bachelor’s degree in Arts from Gettysburg College, Pennsylvania.
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
Eksik bölüm mü var?
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jen Nwankwo, Founder and CEO at 1910 Genetics.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jen, covering:
Being the first PHD at Bain's Global HQ, and what she learned from the experienceHow she stumbled across AI and open innovation as it applied to R&D productivity, and accelerating clinical trialsThe founding story of 1910, and fundraising as an African American female entrepreneur and going on to be backed by Sam Altman, CEO of OpenAI, Y Combinator and Microsoft...Signing a five-year agreement with Microsoft to create an AI-driven drug discovery and development platform that helps R&D teams generate drugs faster and cheaperWhy artisanal and serendipitous drug development does not cut it. And the spectrum of AI experts Vs AI novices in pharma... and why a 'FOMO attitude' will lead to 'pilot fatigue', and slow adoptionBefore founding 1910, Jen worked at the intersection of life science, technology, and business. Prior roles include Management Consultant at Bain & Company, Director of Business Development at a health-tech startup (pre-seed to Series A), and drug discovery stints at Novartis and Eli Lilly. During her Ph.D. research, Jen was an HHMI Predoctoral Fellow at the medical schools of Tufts University and Harvard University.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Karen Lackey, CEO at X-Chem.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Karen, covering:
Why diversity of thought is essential in solving problems that have never been solved beforeWhy did she leave the big pharma world after 30 years to join the world of academia? And how joining a global CRO enabled Karen to democratize its tech and platformsWhy she's taking her decades of drug discovery experience to help redefine it at X-ChemUsing AI/ML more holistically to make its innovative platform more accessible and capital-efficient to biotechs dealing with challenging small molecule projectsHer view on biotech failures and fragmented space and the need to rethink ways to launch biotechsKaren Lackey is the Chief Executive Officer of X-Chem, a company dedicated to delivering on the promise of a leading small molecule drug discovery partner with unmatched excellence in DNA encoded library technology, digitized drug discovery, and discovery chemistry.
Karen's over 30-year career encompasses international leadership roles within Pharma (GSK, Roche), Academia (MUSC, UA), Biotech (e.g. PyramidBio, BlinkBio, Centauri, Aurobac), Foundations/Charities (e.g. CRUK, TI Horizons) and most recently with the CRO Evotec. She is a passionate drug hunter, playing a pivotal role in discovering Tykerb, and contributing to the advancement of numerous clinical candidates and launched drugs.
Throughout her distinguished career, Karen has been at the forefront of integrated drug discovery, spanning diverse areas such as machine learning/AI/computational chemistry, medicinal chemistry, chemical biology, biochemistry, discovery biology, pharmacology, DMPK, and the application and integration of new technologies.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Emma Banks, CEO at ramarketing.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Emma Banks, CEO at ramarketing, covering:
How a conversation with her late father led Emma to look out for herself and jump into the unknownThe contrast of two different CEO roles - stepping from a hand-to-mouth cash-strapped tech business into a rapid-growth businessWhy Emma decided to do the UNTHINKABLE...and work with Raman to run ramarketingThe one piece of advice that has helped Emma navigate being a CEO under PE ownershipAnd why, despite some challenges on the horizon...the only way is up for the pharma services spaceHaving spent over 20 years of experience in the industry with a focus on clinical research and a former board member of the Society of Clinical Data Management (SCDM), Emma is a seasoned expert in the global pharmaceutical and life sciences contract services sector.
After earning a PhD in Immunology and two years of postdoctoral research, Emma led the data management team at a small biometrics CRO before going on to run an international life sciences software business.
Today, Emma heads up ramarketing, overseeing growth plans across North America and Europe, ensuring exceptional service to clients looking to grow in life sciences.----more----
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.----more----
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Rani Powers, Founder & CEO at Pluto Bio.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rani, covering:
Her passion for coding and what drew her into the world of biologyHow the frustration of using clunky software in the lab led to the exploration of a better alternative... and eventually her own start-upThe value of continuous user testing in building a solution that truly works and bringing joyful experiences to biologistsSpinning out her company from the Wyss Institute at Harvard University... in a non-conventional wayHow the adoption and implementation of AI is just getting started... and how it will evolveDr Rani Powers is the Founder & CEO at Pluto. She is a computational biologist, software developer, and product leader, helping biologists interface deeply with their data to make new discoveries faster.
She has expertise in deep learning, molecular biology, -omics data & product management, all focused on accelerating drug discovery with beautiful, collaborative software.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tamar Thompson, Head of Global Corporate Affairs at Alexion, AstraZeneca Rare Disease.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology space with Tamar, covering:
The epidemiological challenge of rare diseases and representing the topic at the White HouseWhy is rare disease drug development so hard, but why is there so much interest in the area given the tech advancements?The value and impact of an acquisition for mid-sized biotech by pharma giant AstraZenecaSome top tips from the perspective of being a minority, female leader in the industry... and the importance of finding your championsTamar leads global corporate affairs and is responsible for communications, government affairs, and policy for Alexion. In addition, she serves as Chairwoman of the Board for Alexion’s charitable foundation and the Alexion lead for Inclusion and Diversity.
Before Alexion, Tamar led Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb. Tamar has more than 20 years of progressive healthcare experience spanning across several industry sectors.
Tamar holds a M.S. in Health Sciences with a concentration in Public Health from Trident University. Tamar also serves as Chair at MassBio, is on the board of directors for the Boston Chamber, and sits on the Schwartz Center (MassGeneral Hospital) Leadership Council.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chris Garabedian, CEO at Xontogeny and Venture Fund Manager at Perceptive Advisors.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chris, covering:
How he utilized his pharma experience to become a CEO and revitalize a biotech company, positioning it for a $15bn market capWhy the biotech space had such a market downturn, and how the uptake in the industry will be data-drivenDemystifying the role of a biotech CEO and understanding what it takes to drive successful drug developmentWhy relying on outsourcing is critical for biotechs todayThe emerging, secondary-tier biotech clusters in the US... but why does Boston remain unrivalled?Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund, which supports early-stage companies with Series A investments across biotech, medtech and healthtech.
Chris has a broad base of experience and a track record of success over his decades-long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial-stage leader in the genetic technology space. He also led Corporate Strategy for Celgene from 2007 to 2010 and served in several global commercial and corporate development leadership roles at Gilead from 1997 to 2005.
He serves on the boards of several life sciences companies and speaks at industry conferences on a wide range of important issues. He is a member of the Corporate Relations Board for the Keck Graduate Institute. He has previously served on the Board of Directors of MassBio and is a Senior Advisor for the Boston Consulting Group.
-----
Join Molecule to Market and ramarketing for an exclusive panel discussion series at this year's CPHI Milan - across 3 power-packed sessions, our industry experts will be sharing insights into driving brand growth with strategic marketing.
Find out more and pre-register here
-----
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kent Payne, CEO at Aliri Bioanalysis.
Your host Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kent, covering:
Being exposed to scientific efficiencies early on in his career as a bench scientist, and what it took to bring a successful NDA to marketThe formative years of Catalent, and helping to establish its early biologics and bioanalysis capabilitiesHe shares his core principles playbook for getting a company back on track and on a path for growthThe value of getting scientists in front of the client to build relationships and demonstrate technical know-howThe strong fundamentals that attracted him to Aliri, and having hot RNA therapeutic capabilities to offer the marketHow Aliri was formed through the merger of three well-established players in the bioanalytical space: Tandem Labs, Pyxant Labs, and ImaBiotechDr. Kent Payne is distinguished as a business operator and leader in sales, commercial manufacturing, and product development. He has extensive executive experience in M&A and successfully running start-up, growth, and turnaround businesses in Fortune 500 and Private Equity environments. Kent currently serves as the CEO of Aliri Bioanalysis (an Archimed investment company) and board director for GBI (a Signet Healthcare Partners company). He previously served as the CEO of BioDuro-Sundia, LLC (an Advent International company)
Aliri Bioanalysis is celebrating the 30th anniversary of its operations in Salt Lake City, Utah, which coincidently, is also the location of the AAPS annual meeting this year. Kent and team are marking this special occasion during the conference where they will showcase their technical expertise with over a dozen scientific posters and presentations. He also wanted to let our listeners know that his team would be happy to host personal tours of their lab in Salt Lake to those attending the conference. Simply email [email protected] to learn more.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA).
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering:
The evolution of the PBOA over the last decade, the impact of M&A on the Association, and building a safe place where CDMOs belongHow the industry has evolved over the last few years after Covid, including harder times and areas of green shootsWhy Gil believes Novo's purchase of Catalent is a black swan event and not a new megatrendA deeper dive into fine details of The BIOSECURE Act, and its potential impact on the CDMO space over the next 7-8 yearsThe need to know market headwinds and tailwinds that you simply cannot ignoreGil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA's annual members-only Meeting & Conference.
Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called the Virtual Memories Show (https://chimeraobscura.com/vm)
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steven Chevillotte, Chief Executive Officer at SaniSure.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steven, covering:
Building a great partner through professionalization and integration while retaining founder DNA of entrepreneurship and innovationThe transformation of quality components and complex assemblies to game changing systems and solutionsHow SaniSure differentiates from smaller and larger bioprocessing organizationsWhy exceptionally robust and clean products coupled with excellence in customized components and designing flow paths make SaniSure the partner of choice for Advanced Therapies (Eg: Cell Therapy)Making the bioprocessing supply chain more robustSaniSure CEO Steven has held senior leadership roles in finance, operations, and general management at precision manufacturing businesses, always in highly engineered and highly regulated industries, including Class III Medical Devices and Aerospace & Defense. Has learned best practices at large public and private companies and has developed an expertise and passion for hands-on transformation through strategy deployment. He is experienced with M&A and integration in PE-backed environments and has led a successful exit process. Steve holds Masters degrees in Manufacturing Systems Engineering and Financial Analysis & Accountancy.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping comp
-
In this mid year episode special, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the trends happening across the life sciences and outsourcing space in 2024.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain covering:
The anticipated recovery of the biotech sector and where it stands now Geopolitical influences on the life sciences industry, with a focus on the CDMO sector Exciting upcoming episodes and insights to watch for in the next few weeks Where to meet Raman at upcoming trade shows across North America & Europe Sectors powering through industry challenges, including early-stage development and AI-driven drug discoverySubscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Yussuf Goolam, Co-Founder, President and CEO at RxSource.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Yussuf, covering:
His family's journey from Mozambique to North America and the value of having an entrepreneurial ethosLifelong business lessons from a window cleaning job... and the impact of going on a learning rampageThe real-life grind of getting a business off the ground and always being willing to chase an opportunityThe pivot that led to becoming a global partner for clinical trial supplies and not just a transactional sourcing supplierThe importance of purpose, mission, values, culture and clarity in building a fiercely loyal and fulfilled workforceAfter co-founding RxSource in 2005, Yussuf’s initial focus was developing and expanding the company’s brand and client base globally. In early 2020, he assumed a new role as President and CEO and guided the organisation through a significant transformation. Since shifting the focus to clinical trial supply chain services, the company has grown to over 60 team members worldwide, supporting CROs, biotechs, and sponsors.
With over 20 years of experience in the niche pharmaceutical sector, he is dedicated to building a purpose-driven company by supporting a team of high-performing individuals to achieve their personal and professional goals together.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kevin Cook, CEO at Sterling Pharma Solutions.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kevin, covering:
Decades of mixed ownership and conflicting business models led to lots of character-building learnings... and the rebirth of SterlingThe power of a rebrand and sense of togetherness to gain commercial tractionKevin’s five-point M&A playbook that’s helped drive exponential, transatlantic growthWhy culture and people are the hardest things when scaling from 180 colleagues on one site to a 1300+ strong team across six sitesThe robustness of small molecules, on-shoring back to the West and reasons to be optimistic for the futureKevin has over 30 years of experience in the pharmaceutical industry. He started working with Robinson Brothers as an Assistant Plant Manager before progressing to Senior Plant Manager. Kevin then joined Boots Pharmaceuticals with responsibility for commissioning activities on a new pharmaceutical plant.
In 1993 Kevin joined Sterling Organics and has supported the site through several mergers and acquisitions over 18 years. At that time, he was Operations Director for Chirex, Industrial Director for Rhodia Pharma Solutions, and President of Shasun Pharma Solutions.
In 2010, Kevin joined Aesica Pharmaceuticals as the Managing Director for the API business unit with a clear focus on growth through increasing the customer and product portfolio. Kevin returned to Shasun Pharma Solutions in 2013 to take responsibility for all commercial activities relating to the pharmaceutical service business. Having overseen the launch of Sterling Pharma Solutions as an independent CDMO, he was appointed CEO, President, and Board Member.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Vijay Vaswani, Co-Founder & CEO at Omniscope.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vijay, covering:
How travel expands the mind and enables you to amplify your networkThe founding story of Omniscope and its mission of using tech to help unlock the immune systemAI can read the immune system in HD, helping with clinical trials and predictive candidate selectionHow you should be thinking about AI for drug discovery and drug developmentAnd what the t-shirt he wears at work says on the front...Vijay Vaswani views technology as fundamental to humanity. He has been involved in scaling companies such as Illumina and 10X Genomics. During his leadership at Siemens Healthineers and Meridian Biosciences, he acquired and commercialized disruptive diagnostic technologies. Vijay has also participated in important IPOs in the biotechnology industry and finds his passion in improving health through the application of technology.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.
See you at BPI!
M2M host, Raman Sehgal will be attending the BPI event in Boston this September. The BPI team has given M2M listeners an exclusive discount code for event passes - enjoy 30% off using the code MOLECULE30 or follow this link: https://informaconnect.com/bioprocessinternational/?vip_code=MOLECULE30&utm_source=molecule2market&utm_medium=website
Don't miss out and we'll see you in September!
-
In this episode of Molecule to Market, you’ll go inside the global drug development and GMP Manufacturing space with David Staunton, Head of Life Sciences Transformation at Cognizant.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:
Why being a supplier is harder if you have not been on the client side An industry driven by change and the importance of digital strategy to drive business outcomes Why pharma companies need to be both big and fast to win How AI is accelerating promising molecules and leading to GMP Manufacturing and supply bottlenecks The future of deployable, modular factories to service population centers that provide better access to personalized medicines How generative AI is impacting the industry right now, and how will this evolve with the introduction of robots (or ‘cobots’)David leads transformation and generative AI, collaborating closely with tier 1 pharma and biotech client teams worldwide. Over the last 25+ years, David has established and directed international teams, pioneering practical, proven, and innovative programs that revolutionize new product introduction (NPI) and GMP manufacturing & supply.
In consistent dialogue with CIOs, Global VPs of Engineering, Quality VPs, and Site Heads of GMP Manufacturing and Lab facilities, David leads the delivery of Transformation Services for Industry 4.0. David is an internationally recognized speaker on Industry 4.0 and has given lectures on various UCD Master’s Programmes.
LinkedIn: (6) David Staunton | LinkedIn
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:
Tom Willson, Vice President of Contract Manufacturing at Pfizer CentreOneHanna Lesch, Chief Technology Officer at Exothera Stephen Grant, entrepreneurial advisor and angel investorYour host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, Hanna, and Stephen, covering:
Unraveling the potential seismic shift in the pharmaceutical outsourcing industry; the BIOSECURE Act and its implicationsWill the BIOSECURE Act accelerate a trend toward a more regionalized approach to drug development and manufacturing?How Biotechs/CDMOs are going to adapt their strategies post BIOSECURE ActWhat impacts BIOSECURE will have on the supply chainThe BIOSECURE Act has the potential to significantly restrict the ability of biotechnology companies to collaborate with certain Chinese companies without losing the ability to contract with the US government. Our guests provide insightful perspectives on the potential implications of this legislation on the supply chain of life-saving drugs across America.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mihaela Simianu, Vice President of R&D and Operations at Singota Solutions.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mihaela, covering:
How having physician parents in Romania motivated Mihaela into a career in the biopharmaceutical space What 17 years at Eli Lilly taught her about drug development and commercialization... and why she ultimately left for Amgen Why, after 25 years on the drug sponsor-side, she opted to move onto the CDMO side The rapid, complex, and fascinating experience of being part of a small CDMO that supports multiple sponsors to serve patients The advisory and execution role of a CDMO partnerDr. Simianu is a transformational leader in the biopharmaceutical industry, renowned for advancing technology and therapeutic products to enhance personalized medicine and public health. She has achieved significant outcomes for multi-billion-dollar organizations, leading to the approval of 20+ new therapeutic agents and the introduction of commercial processes at more than thirty manufacturing sites globally across her tenure with Eli Lilly, Amgen, and Merck.
Her expertise spans multiple disease areas, and she excels in integrating raw material suppliers, facilities, and engineering equipment into pharmaceutical systems. Specializing in modern product development, quality, and manufacturing systems, she has played a pivotal role in injectable drug commercialization and market expansion. She advanced a portfolio of over thirty-five new pipeline products.
Dr. Simianu holds a Ph.D. in Chemistry from Marquette University, an M.S./B.S. in Chemical Engineering from the Babes-Bolyai University of Cluj-Napoca, and a Jack Welch Management Institute certification. She is a recognized international industry expert and has actively volunteered for the Parenteral Drug Association for over 20 years.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Doctor Eric Edwards, Co-Founder and CEO at Phlow.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Eric, covering:
How a life-threatening allergy for him and his identical twin brother led to a career in medicine and then an entrepreneurial journey in the pharma space The journey from inventors to becoming a commercial pharma company... followed by a $310m exit How a plan to support a shortage in critical medicines for children took a turn as the COVID-19 pandemic arrived The US Government awarded a $899m contract to help rebuild the domestic industrial base for Covid medicines and longer-term advanced manufacturing The paradox of innovative, specialty, expensive medicines vs. drug shortages for basic essential medicines that everyone should be able to accessAs CEO, Eric has assembled a world-class team committed to providing a solution to the broken essential medicines supply chain and the overreliance on foreign manufacturers for the US' highest priority medicines.
He previously co-founded Kaléo, where he held several executive management positions, including Chief Science Officer, Chief Medical Officer, and Vice President.
Dr. Edwards is the co-inventor of multiple marketed products for treating allergic emergencies (anaphylaxis), named on over 215 issued and patent-pending applications.
As a Doctor of Medicine and a Biology Ph.D. in Pharmaceutical Sciences, Eric also continues to serve his community by volunteering on a local rescue squad. This includes responding to 911 calls and training paramedics in pre-hospital emergency care.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
-
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Andy Holt, CCO of Viralgen Vector Core.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andy, covering:
Growing a CDMO while dealmaking in a gene therapy company…at the same timeSelling a revenue-generating therapy company to Bayer during the pandemicFaster failure or faster acceleration; the need to celebrate every gene therapy batch as it’s going to save livesThe challenges of manufacturing AAV gene therapies and why the next generation of CGT CDMOs need a voice at the tableAndy has been working on the business side of cell and gene therapy for more than 15 years, focused on creatively connecting science and solutions, whether health care for whale sharks or supporting multi-billion dollar transactions between biotech and big pharma.
Along the way, he has held positions in business development and management for several large CDMOs like Lonza and MilliporeSigma, leadership positions in Askbio, Ncardia, and Cellistic, and his current role as Chief Commercial Officer for Viralgen, a pioneering AAV-focused CDMO leveraging Askbio’s manufacturing expertise for clients around the world.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.
- Daha fazla göster
